Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Multi-center, Open-label Phase Ib/II Study of Gentuximab Injection + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer to Evaluate Tolerability, Safety, Efficacy and Pharmacokinetics.

NCT04053205 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04053205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04053205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Multi-center, Open-label Phase Ib/II Study of Gentuximab Injection + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer to Evaluate Tolerability, Safety, Efficacy and Pharmacokinetics.
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
November 5, 2019
Completion date
September 20, 2020
Enrollment
76 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric or gastroesophageal junction cancer